Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $6.33

ADC Therapeutics SA (NYSE:ADCTGet Free Report) has earned a consensus rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $7.50.

ADCT has been the topic of a number of analyst reports. Guggenheim started coverage on shares of ADC Therapeutics in a research report on Thursday, March 28th. They issued a “buy” rating and a $11.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of ADC Therapeutics in a report on Thursday, March 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of ADC Therapeutics in a research note on Wednesday, March 6th.

Get Our Latest Analysis on ADC Therapeutics

ADC Therapeutics Trading Up 2.9 %

Shares of ADCT stock opened at $4.44 on Thursday. The company has a market capitalization of $366.02 million, a P/E ratio of -1.51 and a beta of 1.73. The business’s 50 day moving average is $4.34 and its two-hundred day moving average is $2.24. ADC Therapeutics has a twelve month low of $0.36 and a twelve month high of $6.04.

Institutional Investors Weigh In On ADC Therapeutics

Several institutional investors have recently made changes to their positions in ADCT. Moneta Group Investment Advisors LLC lifted its stake in shares of ADC Therapeutics by 112,365.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,933,073 shares of the company’s stock valued at $84,223,000 after purchasing an additional 21,913,571 shares during the period. Millennium Management LLC lifted its position in shares of ADC Therapeutics by 709.3% during the 4th quarter. Millennium Management LLC now owns 3,401,120 shares of the company’s stock valued at $13,060,000 after acquiring an additional 2,980,867 shares during the period. Prosight Management LP boosted its stake in shares of ADC Therapeutics by 71.4% during the 2nd quarter. Prosight Management LP now owns 5,583,900 shares of the company’s stock worth $12,005,000 after acquiring an additional 2,326,540 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of ADC Therapeutics by 23,287.6% in the 4th quarter. Bank of America Corp DE now owns 1,604,626 shares of the company’s stock worth $6,162,000 after acquiring an additional 1,597,765 shares during the period. Finally, Perceptive Advisors LLC purchased a new stake in ADC Therapeutics during the first quarter worth $2,917,000. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

About ADC Therapeutics

(Get Free Report

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.

Recommended Stories

Analyst Recommendations for ADC Therapeutics (NYSE:ADCT)

Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.